Post-Market Evaluation of Active Thrombectomy and Proximal Aspiration During Lower Extremity Tibial Interventions

Last updated: April 8, 2025
Sponsor: Protexa Endovascular, Inc.
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Peripheral Arterial Occlusive Disease

Circulation Disorders

Vascular Diseases

Treatment

N/A

Clinical Study ID

NCT06929832
PR-100
  • Ages > 18
  • All Genders

Study Summary

Post-Market Evaluation of Active Thrombectomy and Proximal Aspiration during Lower Extremity Tibial Interventions

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Subject is at least 18 years of age

  2. Subject or authorized representative has signed a written Informed Consent

  3. Subject is willing to comply with the protocol requirements

  4. Rutherford classification 4-6

  5. Planned intervention of the native infrapopliteal arteries using balloonangioplasty, atherectomy, and endovascular procedures.

  6. Reference vessel diameter for intended location of the distal tip funnel deploymentfor the Protexus catheter is ≥3.5mm and ≤6.0mm by visual estimate

  7. Inflow arteries have ≤30% stenosis. Inflow arteries can be treated at the time ofthe study procedure to achieve ≤30% stenosis

Exclusion

Exclusion Criteria:

  1. Prior intervention within 30 days of treatment in the planned deployment site forthe Protexus catheter

  2. Presence of a stent in the planned deployment site for the Protexus catheter

  3. Has perforation, dissection, or other injury of the access vessel or Protexuscatheter deployment site requiring additional stenting or surgical interventionbefore enrollment

  4. History of bleeding diathesis or coagulopathy and unable to receive standardanticoagulation during the index procedure

  5. Acute limb ischemia defined as onset of symptoms within two weeks of the plannedintervention

  6. Inflow arteries have >30% stenosis after treatment at the time of the studyprocedure

  7. Pregnant female subject or subject that has a positive pregnancy test within theprevious 7 days

  8. Known hypersensitivity or allergy to nitinol

  9. Target blood vessels are infected, have extreme tortuosity, or are occluded withcalcified material

Study Design

Total Participants: 20
Study Start date:
April 01, 2025
Estimated Completion Date:
December 31, 2025

Study Description

This is a prospective, multi-center, non-randomized, open label, single arm post-market clinical study to gather data on the use of the Protexus catheter for temporary blood vessel occlusion while standard of care treatment with other therapeutic devices is conducted in patients undergoing infrapopliteal treatment for peripheral arterial disease (PAD).